Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07220213 · ClinicalTrials.gov registry record · NA

FELLAShip to Better Health

A NA study of Diabetes Type 2 and Obesity & Overweight, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT07220213 is a NA study of Diabetes Type 2 and Obesity & Overweight that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 90 participants, below the 738-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07220213, a NA study of Diabetes Type 2 and Obesity & Overweight, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the FELLAship program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the FELLAship program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.

Interventions

  • BEHAVIORAL FELLAship

Study Locations (1)

Alabama

  • The Worship Center Cristian Church - Birmingham

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2026-01-01
Est. Completion 2027-01-01
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT07220213

The ClinicalTrials.gov registry entry for NCT07220213 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 738-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (88% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Diabetes Type 2 appearing as the primary indexed condition, and to 1 intervention - of which FELLAship is the first listed.

NCT07220213 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT07220213 about?

NCT07220213 is a clinical study titled "FELLAShip to Better Health". The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aim...

What is the current status of trial NCT07220213?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2026-01-01. Estimated completion is 2027-01-01.

What conditions does trial NCT07220213 study?

This clinical trial studies the following conditions: Diabetes Type 2, Obesity & Overweight, Blood Sugar; High, High Cholesterol, High Cholesterol/Hyperlipidemia.

What interventions are being tested in trial NCT07220213?

The interventions under investigation include: FELLAship (BEHAVIORAL).

Who is sponsoring clinical trial NCT07220213?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07220213 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.